^
    Back
    Association details:
    Biomarker:ALK mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    Patients with ALK-rearranged NSCLC should receive first-line ALK TKI including crizotinib [I, A; ESMO-MBCS v1.1 score: 4], ceritinib [I, B; ESMO-MCBS v1.1 score: 4], alectinib [I, A] or brigatinib [I, B; not EMA-approved]…
    DOI:
    Ann Oncol (2018) 29 (suppl 4): iv192–iv237
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

    Excerpt:
    ...- Patient must have been pre-identified as having a tumor with an ALK or ROS1 positive mutation, translocation, rearrangement or amplification....
    Trial ID:
    SIGNATURE
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Excerpt:
    Among 80 patients who had received crizotinib previously, the response rate was 56% (95% CI, 45 to 67). Responses were observed in patients with various resistance mutations in ALK and in patients without detectable mutations. Among patients with NSCLC who received at least 400 mg of ceritinib per day, the median progression-free survival was 7.0 months (95% CI, 5.6 to 9.5).
    DOI:
    10.1056/NEJMoa1311107
    Trial ID:
    NCT01283516